{
    "organizations": [],
    "uuid": "16bb9b7253c332230d214ff19ccb298b551464c9",
    "author": "Charley Grant",
    "url": "https://www.wsj.com/articles/generic-deal-blowup-is-a-reminder-that-character-matters-1519749992",
    "ord_in_thread": 0,
    "title": "How Missed Red Flags Derailed a Drug Deal",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "A bombshell revelation seems likely to derail a generic-drugs merger. Investors could have avoided the mess altogether by taking some red flags more seriously.\n\nGerman health-care company Fresenius SE said Monday it was investigating “alleged breaches of [Food and Drug Administration] data integrity requirements” at generics-drug manufacturer Akorn, which Fresenius agreed to purchase last year for $3.7 billion. For their part, Akorn said in a statement that its own investigation “has not found any facts that would result in...  ",
    "published": "2018-02-27T18:51:00.000+02:00",
    "crawled": "2018-02-27T21:19:40.036+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "bombshell",
        "revelation",
        "seems",
        "likely",
        "derail",
        "merger",
        "investor",
        "could",
        "avoided",
        "mess",
        "altogether",
        "taking",
        "red",
        "flag",
        "seriously",
        "german",
        "company",
        "fresenius",
        "se",
        "said",
        "monday",
        "investigating",
        "alleged",
        "breach",
        "food",
        "drug",
        "administration",
        "data",
        "integrity",
        "requirement",
        "manufacturer",
        "akorn",
        "fresenius",
        "agreed",
        "purchase",
        "last",
        "year",
        "billion",
        "part",
        "akorn",
        "said",
        "statement",
        "investigation",
        "found",
        "fact",
        "would",
        "result"
    ]
}